UNSPSC 51434902: Aliskiren/amlodipine/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434902 Aliskiren/amlodipine/hydrochlorothiazide, a Commodity code, covers prescription and over-the-counter medications procured by state and local governments for use in emergency medical services, public health programs, and employee health benefit plans. State and local buyers under this code range from city fire and rescue departments to state health agencies and multistate cooperative purchasing alliances. The actual goods being solicited reflect a broader pharmaceutical procurement landscape than the code name suggests — recent opportunities include advanced life support medications for emergency response, generic multi-source pharmaceuticals distributed through wholesaler networks, and direct-to-manufacturer prescription fulfillment programs designed to improve cost management and supply chain efficiency.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) closing April 8, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP closing March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013, closed April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to bypass traditional pharmacy benefit managers and wholesaler arrangements.